BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 18940747)

  • 1. Risk-reduction surgery in BRCA mutation carriers in a Spanish population: adherence and results.
    Pérez Segura P; Jiménez P; Olivera H; Andrés Conejero R; Caldés T; de la Hoya M; Román JM; Moreno A; Puente J; Díaz-Rubio E
    Clin Transl Oncol; 2008 Oct; 10(10):660-4. PubMed ID: 18940747
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations.
    Casey MJ; Synder C; Bewtra C; Narod SA; Watson P; Lynch HT
    Gynecol Oncol; 2005 May; 97(2):457-67. PubMed ID: 15863145
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Choice of management of southern Chinese BRCA mutation carriers.
    Kwong A; Wong CH; Shea C; Suen DT; Choi CL
    World J Surg; 2010 Jul; 34(7):1416-26. PubMed ID: 20182723
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outcome of risk-reducing salpingo-oophorectomy in BRCA carriers and women of unknown mutation status.
    Manchanda R; Abdelraheim A; Johnson M; Rosenthal AN; Benjamin E; Brunell C; Burnell M; Side L; Gessler S; Saridogan E; Oram D; Jacobs I; Menon U
    BJOG; 2011 Jun; 118(7):814-24. PubMed ID: 21392246
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association between clinical characteristics and risk-reduction interventions in women who underwent BRCA1 and BRCA2 testing: a single-institution study.
    Uyei A; Peterson SK; Erlichman J; Broglio K; Yekell S; Schmeler K; Lu K; Meric-Bernstam F; Amos C; Strong L; Arun B
    Cancer; 2006 Dec; 107(12):2745-51. PubMed ID: 17109443
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcome of preventive surgery and screening for breast and ovarian cancer in BRCA mutation carriers.
    Scheuer L; Kauff N; Robson M; Kelly B; Barakat R; Satagopan J; Ellis N; Hensley M; Boyd J; Borgen P; Norton L; Offit K
    J Clin Oncol; 2002 Mar; 20(5):1260-8. PubMed ID: 11870168
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Breast and ovarian cancer risk perception after prophylactic salpingo-oophorectomy due to an inherited mutation in the BRCA1 or BRCA2 gene.
    Finch A; Metcalfe K; Lui J; Springate C; Demsky R; Armel S; Rosen B; Murphy J; Elit L; Sun P; Narod S
    Clin Genet; 2009 Mar; 75(3):220-4. PubMed ID: 19263514
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical outcome of prophylactic oophorectomy in BRCA1/BRCA2 mutation carriers and events during follow-up.
    Olivier RI; van Beurden M; Lubsen MA; Rookus MA; Mooij TM; van de Vijver MJ; van't Veer LJ
    Br J Cancer; 2004 Apr; 90(8):1492-7. PubMed ID: 15083174
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Utilization of screening and preventive surgery among unaffected carriers of a BRCA1 or BRCA2 gene mutation.
    Wainberg S; Husted J
    Cancer Epidemiol Biomarkers Prev; 2004 Dec; 13(12):1989-95. PubMed ID: 15598752
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Presymptomatic DNA testing and prophylactic surgery in families with a BRCA1 or BRCA2 mutation.
    Meijers-Heijboer EJ; Verhoog LC; Brekelmans CT; Seynaeve C; Tilanus-Linthorst MM; Wagner A; Dukel L; Devilee P; van den Ouweland AM; van Geel AN; Klijn JG
    Lancet; 2000 Jun; 355(9220):2015-20. PubMed ID: 10885351
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer in Women: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.
    Nelson HD; Pappas M; Cantor A; Haney E; Holmes R
    JAMA; 2019 Aug; 322(7):666-685. PubMed ID: 31429902
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of family history on choosing risk-reducing surgery among BRCA mutation carriers.
    Singh K; Lester J; Karlan B; Bresee C; Geva T; Gordon O
    Am J Obstet Gynecol; 2013 Apr; 208(4):329.e1-6. PubMed ID: 23333547
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk management options elected by women after testing positive for a BRCA mutation.
    Garcia C; Wendt J; Lyon L; Jones J; Littell RD; Armstrong MA; Raine-Bennett T; Powell CB
    Gynecol Oncol; 2014 Feb; 132(2):428-33. PubMed ID: 24355485
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prophylactic surgery recommended for BRCA1 carriers.
    Cancer Discov; 2014 May; 4(5):OF1. PubMed ID: 24795013
    [No Abstract]   [Full Text] [Related]  

  • 15. An evaluation of needs of female BRCA1 and BRCA2 carriers undergoing genetic counselling.
    Metcalfe KA; Liede A; Hoodfar E; Scott A; Foulkes WD; Narod SA
    J Med Genet; 2000 Nov; 37(11):866-74. PubMed ID: 11073541
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness of Prophylactic Surgeries in BRCA1 or BRCA2 Mutation Carriers: A Meta-analysis and Systematic Review.
    Li X; You R; Wang X; Liu C; Xu Z; Zhou J; Yu B; Xu T; Cai H; Zou Q
    Clin Cancer Res; 2016 Aug; 22(15):3971-81. PubMed ID: 26979395
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The average cumulative risks of breast and ovarian cancer for carriers of mutations in BRCA1 and BRCA2 attending genetic counseling units in Spain.
    Milne RL; Osorio A; Cajal TR; Vega A; Llort G; de la Hoya M; Díez O; Alonso MC; Lazaro C; Blanco I; Sánchez-de-Abajo A; Caldés T; Blanco A; Graña B; Durán M; Velasco E; Chirivella I; Cardeñosa EE; Tejada MI; Beristain E; Miramar MD; Calvo MT; Martínez E; Guillén C; Salazar R; San Román C; Antoniou AC; Urioste M; Benítez J
    Clin Cancer Res; 2008 May; 14(9):2861-9. PubMed ID: 18451254
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ovarian pathology in risk-reducing salpingo-oophorectomies from women with BRCA mutations, emphasizing the differential diagnosis of occult primary and metastatic carcinoma.
    Rabban JT; Barnes M; Chen LM; Powell CB; Crawford B; Zaloudek CJ
    Am J Surg Pathol; 2009 Aug; 33(8):1125-36. PubMed ID: 19440148
    [TBL] [Abstract][Full Text] [Related]  

  • 19. When to Consider Risk-Reducing Mastectomy in BRCA1/BRCA2 Mutation Carriers with Advanced Stage Ovarian Cancer: a Case Study Illustrating the Genetic Counseling Challenges.
    Speight B; Tischkowitz M
    J Genet Couns; 2017 Dec; 26(6):1173-1178. PubMed ID: 28780755
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pathologic findings in prophylactic oophorectomy specimens in high-risk women.
    Leeper K; Garcia R; Swisher E; Goff B; Greer B; Paley P
    Gynecol Oncol; 2002 Oct; 87(1):52-6. PubMed ID: 12468342
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.